Full and Booster Doses of SARS-CoV-2 mRNA-1273 Vaccine Increase Waning Antibody Levels After Completed Vaccination Among Dialysis Patients at a Large Dialysis Organization

Linda H Ficociello1 Global Medical Office, Fresenius Medical Care, Waltham, MS, USA

https://orcid.org/0000-0003-3523-0028 View further author information

Joanna Willetts1 Global Medical Office, Fresenius Medical Care, Waltham, MS, USAView further author information

Claudy Mullon1 Global Medical Office, Fresenius Medical Care, Waltham, MS, USA

https://orcid.org/0000-0003-1880-5504 View further author information

Curtis Johnson2 Spectra Laboratories, Southaven, MS, USAView further author information

Michael S Anger1 Global Medical Office, Fresenius Medical Care, Waltham, MS, USA

https://orcid.org/0000-0003-0984-4544 View further author information

Jeffrey L Hymes1 Global Medical Office, Fresenius Medical Care, Waltham, MS, USACorrespondence[email protected]
View further author information

References

Moreno NF, McAdams R, Goss JA, Galvan NTN. COVID-19 vaccine efficacy and immunogenicity in end-stage renal disease patients and kidney transplant recipients. Curr Transplant Rep. 2022;2022:1–11. doi:10.1007/s40472-022-00366-1
Google Scholar
Agur T, Ben-Dor N, Herman-Edelstein M, et al. Longevity of humoral response six months following BNT162b2 vaccine in dialysis patients. Front Med. 2022;9:781888. doi:10.3389/fmed.2022.781888
Web of Science ®Google Scholar
Patyna S, Eckes T, Koch BF, et al. Impact of Moderna mRNA-1273 booster vaccine on fully vaccinated high-risk chronic dialysis patients after loss of humoral response. Vaccines. 2022;10:585. doi:10.3390/vaccines10040585
Web of Science ®Google Scholar
Quiroga B, Soler MJ, Ortiz A, et al. Humoral response to third dose of SARS-CoV-2 vaccines in the CKD spectrum. Clin J Am Soc Nephrol. 2022;17:872–876. doi:10.2215/CJN.01770222
PubMed Web of Science ®Google Scholar
Rodríguez-Espinosa D, Broseta JJ, Bedini JL, Rodríguez N, Maduell F. Antibody maintenance and breakthrough infections 6 months after complete COVID-19 vaccination with the mRNA-1273 and BNT162b2 vaccines in hemodialysis patients. Clin Kidney J. 2022;15(4):pages 818–819. doi:10.1093/ckj/sfab282
Web of Science ®Google Scholar
Mulhern JG, Fadia A, Patel R, et al. Humoral response to mRNA versus an adenovirus vector-based SARS-CoV-2 vaccine in dialysis patients. Clin J Am Soc Nephrol. 2021;16:1720–1722. doi:10.2215/CJN.06450521
PubMed Web of Science ®Google Scholar

Full and Booster Doses of SARS-CoV-2 mRNA-1273 Vaccine Increase Waning Antibody Levels After Completed Vaccination Among Dialysis Patients at a Large Dialysis Organization

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Full and Booster Doses of SARS-CoV-2 mRNA-1273 Vaccine Increase Waning Antibody Levels After Completed Vaccination Among Dialysis Patients at a Large Dialysis Organization

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date